vTv Therapeutics Inc. (VTVT)
| Market Cap | 96.66M |
| Revenue (ttm) | 5.02M |
| Net Income (ttm) | -15.75M |
| Shares Out | 77.33M |
| EPS (ttm) | -0.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 326,698 |
| Open | 1.30 |
| Previous Close | 1.24 |
| Day's Range | 1.24 - 1.30 |
| 52-Week Range | 0.38 - 2.17 |
| Beta | -1.37 |
| Analysts | Buy |
| Price Target | 4.25 (+240.0%) |
| Earnings Date | Aug 3, 2022 |
About VTVT
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule... [Read more...]
Financial Performance
In 2021, VTVT's revenue was $4.01 million, a decrease of -37.56% compared to the previous year's $6.41 million. Losses were -$12.99 million, 52.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for VTVT stock is "Buy." The 12-month stock price forecast is 4.25, which is an increase of 240.00% from the latest price.
News
vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer
HIGH POINT, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type...
vTv Therapeutics Announces Investment by CinRx Pharma
HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (“CinPax”), a subsidia...
vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Stu...
Results confirmed TTP399 improves glycemia without increasing hypoglycemia and suggest a protective effect of TTP399 against DKA in individuals with T1D Results confirmed TTP399 improves glycemia withou...
vTv Therapeutics (VTVT) Stock Surges 41% on Major Investment News
vTv Therapeutics (VTVT) stock is taking off on Wednesday after entering into a funding and collaboration agreement with G42 Investments. The post vTv Therapeutics (VTVT) Stock Surges 41% on Major Invest...
vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 He...
HIGH POINT, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd...
3 Oversold Biotech Stocks to Buy Now
Looking for oversold biotech stocks? These three have all seen significant drops this year despite promising catalysts for the future.
vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022, and provided an update on the progress...
vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update
HIGH POINT, N.C. , March 29, 2022 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the fourth quarter and year ended December 31, 2021, and provided an update on...
vTv Therapeutics Announces CEO Transition
HIGH POINT, N.C., March 3, 2022 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 di...
vTv Therapeutics Shares Updated Corporate Presentation
HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, ...
3 Stocks That Can Make You Rich in Just a Few Years
Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed.
vTv Therapeutics Pulls The Plug On Psoriasis Candidate; Cuts Workforce By 65%
vTv Therapeutics Inc (NASDAQ: VTVT) has decided to shift focus and prioritize its lead program TTP399 as it gears up for Phase 3 pivotal trials. See the pipeline here.
Dow Jones Newswires: VTv Therapeutics slashes 65% of workforce, focuses on its diabetes drug
VTv Therapeutics Inc. said it reduced its workforce by about 65% as it prioritizes development of diabetes drug TTP399.
vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations
-Workforce reduction of 65%
Here's Why vTv Therapeutics (VTVT) is Poised for a Turnaround After Losing 15.2% in 4 Weeks
vTv Therapeutics (VTVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in rev...
VTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates
vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 71.43% and 130.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provided an update on the pro...
Earnings Preview: vTv Therapeutics (VTVT) Q3 Earnings Expected to Decline
VTv Therapeutics (VTVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
vTv Therapeutics Announces Deepa Prasad as New President and CEO
HIGH POINT, N.C., Oct. 20, 2021 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 di...
vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with ...
Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels
vTv Therapeutics Stock Gains As Psoriasis Candidate Shows Favorable Safety Profile
vTv Therapeutics Inc (NASDAQ: VTVT) announced the results of a multiple ascending dose study evaluating HPP737 in healthy adults. HPP737 is an orally administered phosphodiesterase type 4 (PDE4) in...
vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inh...
HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects
Down 16.1% in 4 Weeks, Here's Why vTv Therapeutics (VTVT) Looks Ripe for a Turnaround
vTv Therapeutics (VTVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in rev...